menu

coreCOPD | Core Outcome Set for Stable Chronic Obstructive Pulmonary Disease

Overview

In December 2020, the Green Park Collaborative (GPC), a major initiative of the Center for Medical Technology Policy (CMTP), and the COPD Foundation launched coreCOPD. The goal of coreCOPD is to develop a core set of outcomes for late phase clinical trials of therapies for stable chronic obstructive pulmonary disease (COPD).

COPD is a condition with persistent respiratory symptoms and chronic airflow limitation, caused by a mixture of small airways disease and parenchymal destruction. The clinical outcome measures that are most widely used in stable COPD trials do not give a complete or fully patient-relevant basis to evaluate and compare the clinical benefit of new therapies. Patients and other stakeholders have not yet agreed on which outcomes are most important for their decisions, so researchers cannot fully address this gap.

Approach

coreCOPD uses a structured consensus process. It engages patients, clinicians, researchers, regulators, payers, health technology assessors, product developers and other key stakeholders to agree on the core outcome set. This is the same multi-stakeholder consensus method that GPC uses for its other core outcome set initiatives, such as coreASTHMA and coreHEM.

A core outcome set gives trials a common minimum set of outcomes to measure and report. When studies use the same outcomes, decision makers can compare and combine their results more easily (see the GPC paper A Multi-Pronged Strategy to Improve the Relevance, Usefulness, and Comparability of Outcomes in Clinical Research). A 2022 study in ERJ Open Research named the coreCOPD group as an ongoing effort that aims to harmonise and inform future clinical trial design in COPD.

Partners

GPC carries out coreCOPD in partnership with the COPD Foundation, a 501(c)(3) not-for-profit organization founded in 2004.

Sources